



Science Brief: Background Rationale and Evidence for COVID-19 People

Updated Mar. 8, 2021

[Print](#)

Key Points

- COVID-19 vaccines currently authorized in the United States are effective against COVID-19, including severe disease.
- Preliminary evidence suggests that the currently authorized COVID-19 vaccines may provide some protection against a variety of strains, including B.1.1.7 (originally identified in the United Kingdom). However, reduced antibody neutralization and efficacy have been observed for the B.1.351 strain (originally identified in South Africa).
- A growing body of evidence suggests that fully vaccinated people are less likely to have asymptomatic infection and potentially less likely to transmit SARS-CoV-2 to others. However, further investigation is ongoing.
- Modeling studies suggest that preventive measures such as mask use and social distancing will continue to be important during vaccine implementation. However, there are ways to take a balanced approach by allowing vaccinated people to resume some lower-risk activities.
- Taking steps towards relaxing certain measures for vaccinated persons may help improve COVID-19 vaccine acceptance and uptake.
- The risks of SARS-CoV-2 infection in fully vaccinated people cannot be completely eliminated as long as there is continued community transmission of the virus. Vaccinated people could potentially still get COVID-19 and spread it to others. However, the benefits of relaxing some measures such as quarantine requirements and reducing social isolation may outweigh the residual risk of fully vaccinated people becoming ill with COVID-19 or transmitting the virus to others.
- [Guidance for fully vaccinated people](#) is available and will continue to be updated as more information becomes available.

Background

Comprehensive prevention measures are critical strategies to reduce the burden of SARS-CoV-2 in the United States. These prevention measures include wearing a mask, maintaining at least six feet of physical distance from others, avoiding crowds, avoiding poorly ventilated spaces, hand hygiene, cleaning and disinfection, following [CDC travel guidance](#), and following workplace or school guidance related to personal protective equipment use or SARS-CoV-2 testing ¹.

COVID-19 vaccination is an additional critical prevention measure to help end the COVID-19 pandemic. There are currently three COVID-19 vaccines authorized by the Food and Drug Administration for emergency use: two mRNA vaccines (Pfizer-BioNTech, Moderna) and one viral vector vaccine (Janssen [Johnson & Johnson]). People are considered fully vaccinated if they are ≥ 2 weeks following receipt of the second dose in a 2-dose series (mRNA vaccines), or ≥ 2 weeks following receipt of a single-dose vaccine (Janssen).

While some prevention measures will continue to be necessary regardless of vaccination status, fully vaccinated persons may be able to engage in some activities with low or reduced risk of acquiring or transmitting COVID-19. The benefits of avoiding disruptions such as unnecessary quarantine and social isolation may outweigh the residual risk of becoming ill with COVID-19

or transmitting the virus to others. The ability of vaccinated people to gradually resume some aspects of normal life will optimize well-being and may help improve vaccine acceptance ².

Public health recommendations for people fully vaccinated with COVID-19 vaccines must consider the evidence, including vaccine efficacy against symptomatic and asymptomatic COVID-19, as well as vaccine impact on SARS-CoV-2 transmission. However, other individual and societal factors are important when evaluating the benefits and potential harms of prevention measures among vaccinated individuals. The Advisory Committee on Immunization Practices and CDC routinely consider factors such as population values, acceptability among stakeholders, and feasibility of implementation when making vaccine recommendations ³. These considerations are also useful when making public health recommendations for fully vaccinated people.

In this scientific brief, we summarize evidence available through March 3, 2021 for the currently authorized COVID-19 vaccines (administered according to the recommended schedules) and additional considerations used to inform public health recommendations for fully vaccinated people, including:

- Vaccine efficacy and effectiveness against SARS-CoV-2 infection
- Vaccine performance against emerging SARS-CoV-2 variant strains
- Impact of prevention measures in the context of vaccination
- Population attitudes and behaviors towards vaccination and prevention measures

COVID-19 vaccine efficacy and effectiveness

Vaccine efficacy refers to how well a vaccine performs in a carefully controlled clinical trial, whereas effectiveness describes its performance in the real world. Evidence demonstrates that the authorized COVID-19 vaccines are both efficacious and effective against symptomatic, laboratory-confirmed COVID-19, including severe forms of the disease. In addition, a growing body of evidence suggests that COVID-19 vaccines may also reduce asymptomatic infection, and potentially transmission. Substantial reductions in SARS-CoV-2 infections (both symptomatic and asymptomatic) will have the positive benefit of helping to reduce overall levels of disease, and therefore, transmission in the United States. However, further investigations are ongoing to assess the impact of COVID-19 vaccination on transmission.

Animal challenge studies

Rhesus macaque challenge studies provided the first evidence of the potential protective effects of Pfizer-BioNTech, Moderna, and Janssen COVID-19 vaccines against SARS-CoV-2 infection, including asymptomatic infection. Vaccinated macaques developed neutralizing antibodies that exceeded those in human convalescent sera and showed no or minimal signs of clinical disease after SARS-CoV-2 challenge ⁴⁻⁶. In addition, COVID-19 vaccination prevented or limited viral replication in the upper and lower respiratory tracts, which may have implications for transmission of the virus among humans ⁴⁻⁶.

Vaccine efficacy from human clinical trials

Clinical trials have demonstrated the authorized COVID-19 vaccines to be efficacious against laboratory-confirmed, symptomatic COVID-19, including severe forms of the disease, with evidence for protection against asymptomatic SARS-CoV-2 infection as well ⁷⁻¹³ (**Box 1**).

Box 1. Summary of vaccine efficacy estimates for authorized COVID-19 vaccines

All authorized COVID-19 vaccines demonstrated efficacy (range 65% to 95%) against symptomatic laboratory-confirmed COVID-19.

- For each authorized COVID-19 vaccine, the overall efficacy was similar to the efficacy across different populations, including elderly and younger adults, in persons with and without underlying health conditions, and in persons representing different races and ethnicities.

All authorized COVID-19 vaccines demonstrated high efficacy ($\geq 89\%$) against COVID-19 severe enough to require hospitalization.

All authorized COVID-19 vaccines demonstrated high efficacy against COVID-19 associated death.

- In the vaccine trials, no participants who received a COVID-19 vaccine died from COVID-19; the Moderna and Janssen trials each had COVID-19 deaths in the placebo arm.

Preliminary data suggest COVID-19 vaccination may also protect against asymptomatic infection.

- In the Moderna trial, among persons who had received a first dose, the number of asymptomatic persons who tested positive for SARS-CoV-2 at their second-dose appointment was approximately two-thirds lower among vaccines than among placebo recipients (0.1% and 0.3%, respectively)
- Efficacy of Janssen COVID-19 vaccine against asymptomatic seroconversion was 74% in a subset of trial participants.

No trials have compared efficacy between any of the authorized vaccines in the same study at the same time.

- All Phase 3 trials differed by calendar time and geography.
- Vaccines were tested in settings with different background COVID-19 incidence and circulating variants.

Real-world vaccine effectiveness

Preliminary analyses from the United States, United Kingdom, and Israel demonstrate that a two-dose mRNA COVID-19 vaccination series is highly effective against SARS-CoV-2 infection (including both symptomatic and asymptomatic infections). In the United States, the effectiveness of mRNA COVID-19 vaccination (either Pfizer-BioNTech or Moderna) was 89% against SARS-CoV-2 infection; vaccinated persons who were diagnosed with COVID-19 had a 60% lower hospitalization rate than unvaccinated persons ¹⁴. Among U.K. healthcare personnel, Pfizer-BioNTech COVID-19 vaccination was 86% effective against SARS-CoV-2 infection ¹⁵. In U.K. adults aged ≥ 80 years, including those with multiple underlying medical conditions, vaccine efficacy against symptomatic disease was estimated at 85% ¹⁶. In Israel, two doses of Pfizer-BioNTech COVID-19 vaccine was 90–94% effective against a spectrum of illness: asymptomatic SARS-CoV-2 infection, symptomatic COVID-19, as well as specifically severe COVID-19 ¹⁷. Preliminary data from Israel suggest that persons vaccinated with Pfizer-BioNTech COVID-19 vaccine who develop COVID-19 have a four-fold lower viral load than unvaccinated persons ¹⁸. This observation may indicate reduced transmissibility, as viral load has been identified as a key driver of transmission ¹⁹.

Vaccine performance against emerging SARS-CoV-2 variant strains

SARS-CoV-2 [variants of concern](#) (B.1.1.7 [first described in the United Kingdom]; B.1.351 [first described in South Africa]; P.1 [first described in Brazil]) have emerged with mutations that alter the receptor binding domain of the spike protein (notably the N501Y mutation occurring in all three variants, as well as E484K and E417T/N mutations in B.1.351 and P.1) ²⁰⁻²³. These mutations appear to confer greater resistance to neutralization by sera from persons vaccinated with COVID-19 vaccines, raising concerns that these vaccines may have reduced effectiveness against COVID-19 illness, particularly against the B.1.351 variant. Therefore, vaccine performance against emerging SARS-CoV-2 variants is an important consideration when evaluating the need for continued prevention measures in vaccinated persons, and will require continued monitoring.

Immunogenicity

Sera from mRNA COVID-19 vaccine (both Pfizer-BioNTech and Moderna) recipients have generally demonstrated modest reductions in antibody neutralization activity against a variety of mutations; one study demonstrated poor neutralization activity for B.1.351 ²⁴⁻⁴⁸. Across studies, the greatest reductions were observed for B.1.351, followed by P.1 and P.2 (another variant first described in Brazil); reductions for B.1.1.7 were minimal. The E484K mutation alone or in combination with other mutations in the receptor binding domain has been shown to account for the majority of reduction in vaccine-induced neutralizing antibody activity for the B.1.351, P.1, and P.2 variants ^{26, 29, 31, 42, 43}. For the Janssen viral vector COVID-19 vaccine, spike protein-specific antibody levels and seroresponse rates were similar between U.S. clinical trial participants and participants from Brazil and South Africa, where the viral variants were circulating ⁸. In the absence of a biological correlate of protection, it is difficult to predict how reduced immunogenicity may affect COVID-19 vaccine effectiveness. However, across studies, antibody neutralizing activity of sera from vaccinated persons was still generally higher than that observed for convalescent sera from persons who have recovered from COVID-19 ^{26, 27, 30-32, 36-39, 41-43, 48}.

Efficacy and effectiveness

As described above, preliminary results from the United Kingdom demonstrate that vaccination with two doses of Pfizer-BioNTech COVID-19 vaccine was highly effective (85–86%) against SARS-CoV-2 infection and symptomatic COVID-19 during a period when B.1.1.7 was the predominant circulating strain^{15, 16}. Similarly, high Pfizer-BioNTech vaccine effectiveness (92%) against infection was observed in Israel in the context of multiple circulating strains, with the proportion of cases due to the B.1.1.7 variant increasing to 80% towards the end of the evaluation period¹⁷. Preliminary data suggest that the Janssen COVID-19 vaccine may have reduced overall efficacy against the B.1.351 variant⁸. In the United States, efficacy was 74% and in Brazil (where ~69% of infections were due to P.2) efficacy was 66%, but in South Africa (~where 95% of infections were due to B.1.351) efficacy was 52%^{8, 11}. However, Janssen vaccine efficacy against severe or critical disease was high and similar across sites (73–82%)⁸.

Impact of prevention measures in the context of vaccination

Individual and community-level prevention measures have been shown to help reduce the spread of SARS-CoV-2. These measures form the cornerstone for strategies to reduce viral transmission in the United States^{1, 49-53}. However, there are individual and societal costs related to physical distancing, quarantine, school and business closures, and other prevention measures⁵⁴⁻⁶¹.

Modeling studies suggest that adherence to prevention measures, such as wearing masks and physical distancing, will continue to be important in the context of vaccine implementation⁶²⁻⁶⁸. In one study, complete relaxation of prevention measures prior to adequate vaccination coverage resulted in essentially no reductions in SARS-CoV-2 infections⁶². However, preliminary data suggest that rapidly increasing vaccination rates may allow for the phasing out of some prevention measures as coverage increases⁶⁸ [CDC unpublished]. Furthermore, there may be certain activities that can be performed after vaccination, such as nursing home visitation, as long as other measures are maintained [CDC unpublished].

In summary, prevention measures will continue to be important for all people, regardless of vaccination status, especially during this period of vaccine deployment. However, as vaccination coverage increases, a balanced, stepwise approach to phasing out certain prevention measures in fully vaccinated people, ideally those that are the most disruptive to individuals and society, can be taken.

Population attitudes and behaviors towards vaccination and prevention measures

In surveys conducted since vaccination started in December 2020, approximately two-thirds of U.S. adults stated that they were at least somewhat likely to receive a COVID-19 vaccine (or had received one already)⁶⁹⁻⁷¹. This suggests that continued efforts are needed to strengthen vaccine confidence and uptake, including addressing common concerns around COVID-19 vaccines (such as vaccine side effects, the speed of vaccine development, and mistrust of government), improving health equity by removing barriers to vaccine access, and using evidence-based approaches to improving uptake such as providing incentives for vaccination^{70, 72}. Leading reasons cited by U.S. adults for intending to be vaccinated include being able to return to more normal life, feeling safe around other people, and resuming activities like going to work or school^{2, 73}. Although it remains unknown which of these incentives would achieve the greatest increases in vaccination, information about activities that fully vaccinated people can safely undertake must be communicated in a clear and unambiguous fashion. Maintaining a requirement to continue all prevention measures after vaccination may disincentivize vaccine uptake. In a recent survey, one in five people reported being less likely to get vaccinated if they heard that they will need to continue to wear a mask and practice social distancing even after getting vaccinated².

According to a survey conducted right as the first COVID-19 vaccine was authorized in the United States, most people expected it would take at least 6 months after vaccine rollout before they were able to resume activities such as going out to dinner, going to a gym class, or staying in a hotel⁷⁴. However, a survey conducted less than 2 months into the vaccination program suggest that over half of the general U.S. adult population have already started resuming some of these activities despite the risk of COVID-19 because they “just want their life back”⁷⁵. Reasons for taking fewer COVID-19 precautions than they did a month ago included COVID-19 fatigue, belief that population-based immunity has been achieved through vaccination or disease, belief about reduced disease risk for themselves as others get vaccinated, belief that they no longer pose a threat to high-risk people because high-risk groups are receiving protection through vaccination, and receipt of the vaccines themselves⁷⁵.

In summary, relaxing certain prevention measures for fully vaccinated persons may be a powerful motivator for vaccination, and thus should be an important goal of the U.S. vaccination program.

Conclusions

COVID-19 vaccines currently authorized in the United States have been shown to be efficacious and effective against SARS-CoV-2 infections, including asymptomatic infection, symptomatic disease, severe disease, and death. These findings, along with the potential for reduced viral load in vaccinated persons who develop COVID-19, suggest that any associated transmission risk is likely to be substantially reduced in vaccinated people. While vaccine efficacy against emerging SARS-CoV-2 variants remains under investigation, preliminary evidence suggests that the COVID-19 vaccines presently authorized in the United States will likely be effective against emerging variants, though reduced antibody neutralization and efficacy has been observed for the B.1.351 variant.

Evidence suggests the U.S. COVID-19 vaccination program has the potential to substantially reduce the burden of disease in the United States by preventing illness in fully vaccinated people and interrupting chains of transmission. The risks of SARS-CoV-2 infection in fully vaccinated people cannot be completely eliminated in the setting of continued widespread community transmission of the virus. Vaccinated people could potentially still become infected and spread the virus to others. However, the benefits of avoiding disruptions such as unnecessary quarantine and social isolation may outweigh these potential residual risks. A balanced approach to phasing out certain prevention measures may be a powerful motivator for vaccination, and thus should be an important goal of the U.S. vaccination program.

References
















Note: Preprints have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information.

1. Honein MA, Christie A, Rose DA, Brooks JT, Meaney-Delman D, Cohn A, et al. Summary of Guidance for Public Health Strategies to Address High Levels of Community Transmission of SARS-CoV-2 and Related Deaths, December 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69(49):1860-7.
2. Kaiser Family Foundation. KFF COVID-19 Vaccine Monitor: January 2021 <https://www.kff.org/report-section/kff-covid-19-vaccine-monitor-january-2021-vaccine-hesitancy> [Access date: March 4, 2021] [
3. Lee G, Carr W, Group AE-BRW, Group AEBRW. Updated Framework for Development of Evidence-Based Recommendations by the Advisory Committee on Immunization Practices. *MMWR Morb Mortal Wkly Rep.* 2018;67(45):1271-2.
4. Corbett KS, Flynn B, Foulds KE, Francica JR, Boyoglu-Barnum S, Werner AP, et al. Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. *N Engl J Med.* 2020;383(16):1544-55.
5. Mercado NB, Zahn R, Wegmann F, Loos C, Chandrashekar A, Yu J, et al. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. *Nature.* 2020;586(7830):583-8.
6. Vogel A, Kanevsky I, Che Y, et al. BNT162b vaccines are immunogenic and protect non-human primates against SARS-CoV-2. *bioRxiv.* 2020;<https://www.biorxiv.org/content/10.1101/2020.12.11.421008v1.full> [Access date: March 4, 2021].
7. Food and Drug Administration. Moderna COVID-19 vaccine. Vaccines and Related Biological Products Advisory Committee December 17, 2020 Meeting Briefing Document Addendum- Sponsor. <https://www.fda.gov/media/144453/download> [Access date: March 4, 2021].
8. Food and Drug Administration. Janssen COVID-19 vaccine. Vaccines and Related Biological Products Advisory Committee December 17, 2020 Meeting Briefing Document – Sponsor. <https://www.fda.gov/media/146219/download> [Access date: March 4, 2021].
9. Food and Drug Administration. Pfizer-BioNTech COVID-19 vaccine. Vaccines and Related Biological Products Advisory Committee December 10, 2020 Meeting Briefing Document – Sponsor. <https://www.fda.gov/media/144246/download> [Access date: March 4, 2021].
10. Food and Drug Administration. Moderna COVID-19 vaccine. Vaccines and Related Biological Products Advisory Committee December 10, 2020 Meeting Briefing Document – Sponsor. <https://www.fda.gov/media/144452/download> [Access date: March 4, 2021].
11. Food and Drug Administration. Janssen COVID-19 vaccine. Vaccines and Related Biological Products Advisory Committee February 26, 2021 Meeting Briefing Document- Addendum- Sponsor.










<https://www.fda.gov/media/146218/download> [Access date: March 4, 2021].

12. Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial [press release]. <https://ir.novavax.com/node/15506/pdf> [Access date: March 4, 2021]
13. Voysey M, Costa Clemens S, Madhi S, et al. Single dose administration, and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine Lancet (preprint). 2021;https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3779160 [Access date: March 4, 2021].
14. Pawlowski C, Lenehan P, Puranik A, et al. FDA-authorized COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system. medRxiv. 2021;<https://www.medrxiv.org/content/10.1101/2021.02.15.21251623v1.full.pdf> [Access date: March 4, 2021].
15. Hall A, Foulkes S, Saei A, et al. Effectiveness of BNT162b2 mRNA Vaccine Against Infection and COVID-19 Vaccine Coverage in Healthcare Workers in England, Multicentre Prospective Cohort Study (the SIREN Study). Lancet (preprint). 2021;https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3790399 [Access date: March 4, 2021].
16. Bernal J, Andrews N, Gower C, et al. Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in older adults in England medRxiv. 2021;<https://www.medrxiv.org/content/10.1101/2021.03.01.21252652v1> [Access date: March 4, 2021].
17. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med. 2021.
18. Levine-Tiefenbrun M, Yelin I, Katz R, et al. Decreased SARS-CoV-2 viral load following vaccination. medRxiv. 2021;<https://www.medrxiv.org/content/10.1101/2021.02.06.21251283v1.full.pdf> [Access date: March 4, 2021].
19. Marks M, Millat-Martinez P, Ouchi D, Roberts CH, Alemany A, Corbacho-Monne M, et al. Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study. Lancet Infect Dis. 2021.
20. Centers for Disease Control and Prevention. Emerging SARS-CoV-2 Variants <https://www.cdc.gov/coronavirus/2019-ncov/more/science-and-research/scientific-brief-emerging-variants.html> [Access date: March 4, 2021]
21. Faria N, Claro I, Candido D, et al. Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings. <https://virological.org/t/genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-manaus-preliminary-findings/586> [Access date: March 4, 2021]. 2021.
22. Rambaut A, Loman N, Pybus O, et al. Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations. <https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563> [Access date: March 4, 2021]. 2021.
23. Tegally H, Wilkinson E, Giovanetti M, et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medRxiv. 2020;<https://www.medrxiv.org/content/10.1101/2020.12.21.20248640v1.full> [Access date: March 4, 2021].
24. Annavajhala M, Mohri H, Zucker J, et al. A Novel SARS-CoV-2 Variant of Concern, B.1.526, Identified in New York. medRxiv 2021;<https://www.medrxiv.org/content/10.1101/2021.02.23.21252259v1> [Access date: March 4, 2021].
25. Chen R, Zhang Z, Case J, et al. SARS-CoV-2 variants show resistance to neutralization by many monoclonal and serum-derived polyclonal antibodies. Nature Medicine 2021;<https://doi.org/10.1038/s41591-021-01294-w> .
26. Collier D, De Marco A, Ferreira I, et al. SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodies. medRxiv. 2021;<https://www.medrxiv.org/content/10.1101/2021.01.19.21249840v4> [Access date: March 4, 2021].
27. Edara VV, Floyd K, Lai L, Gardner M, Hudson W, Piantadosi A, et al. Infection and mRNA-1273 vaccine antibodies neutralize SARS-CoV-2 UK variant. bioRxiv. 2021;<https://www.biorxiv.org/content/10.1101/2021.02.20.432046v1> [Access date: March 4, 2021].
28. Emary K, Golubchik T, Aley P, et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7). Lancet (preprint). 2021;https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3779160 [Access date: March 4, 2021].
29. Garcia-Beltran WL, EC., St. Denis K, et al. Circulating SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. medRxiv. 2021;<https://www.medrxiv.org/content/10.1101/2021.02.14.21251704v1> [Access date: March 4, 2021].

date: March 4, 2021].

30. Hoffmann M, Arora P, Seidel A, et al. SARS-CoV-2 variants B.1.351 and B.1.1.248: Escape from therapeutic antibodies and antibodies induced by infection and vaccination. *bioRxiv*. 2021;<https://www.biorxiv.org/content/10.1101/2021.02.11.430787v1>  [Access date: March 4, 2021].
31. Jangra S, Ye C, Rathnasinghe R, Stadlbauer D, Krammer F, Simon V, et al. The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera. *medRxiv*. 2021;<https://www.medrxiv.org/content/10.1101/2021.01.26.21250543v1>  [Access date: March 4, 2021].
32. Kuzmina A, Khalaila Y, Voloshin O, et al. SARS CoV-2 escape variants exhibit differential infectivity and neutralization sensitivity to convalescent or post-vaccination sera. *medRxiv*. 2021;<https://www.medrxiv.org/content/10.1101/2021.02.22.21252002v1>  [Access date: March 4, 2021].
33. Liu Y, Liu J, Xia H, Zhang X, Fontes-Garfias CR, Swanson KA, et al. Neutralizing Activity of BNT162b2-Elicited Serum – Preliminary Report. *N Engl J Med*. 2021.
34. Muik A, Wallisch AK, Sanger B, Swanson KA, Muhl J, Chen W, et al. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera. *Science*. 2021.
35. Planas D, Bruel T, Grzelak L, et al. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. *bioRxiv*. 2021;<https://www.biorxiv.org/content/10.1101/2020.12.11.421008v1.full>  [Access date: March 4, 2021].
36. Rathnasinghe R, Jangra S, Cupic A, et al. The N501Y mutation in SARS-CoV-2 spike leads to morbidity in obese and aged mice and is neutralized by convalescent and post-vaccination human sera. *medRxiv*. 2021;<https://www.medrxiv.org/content/10.1101/2021.01.19.21249592v1>  [Access date: March 4, 2021].
37. Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. *medRxiv*. 2020;<https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1>  [Access date: March 4, 2021].
38. Shen X, Tang H, McDanal C, Wagh K, Fischer W, Theiler J, et al. SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines. *Cell Host & Microbe*. 2021;<https://ssrn.com/abstract=3777473>  .
39. Skelly D, Harding A, Gilbert-Jaramillo J, et al. Vaccine-induced immunity provides more robust heterotypic immunity than natural infection to emerging SARS-CoV-2 variants of concern. *Research Square*. 2021;<https://www.researchsquare.com/article/rs-226857/v1>  [Access date: March 4, 2021].
40. Stamatatos L, Czartoski J, Wang Y, al; e. Antibodies elicited by SARS-CoV-2 infection and boosted by vaccination neutralize an emerging variant and SARS-CoV-1. *medRxiv*. 2021;<https://www.medrxiv.org/content/10.1101/2021.02.05.21251182v1>  [Access date: March 4, 2021].
41. Supasa P, Zhou D, Dejnirattisai W, et al. Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. *Cell*. 2021;<https://doi.org/10.1016/j.cell.2021.02.033>  [Access date: March 4, 2021].
42. Tada T, Dcosta BM, Samanovic-Golden M, Herati RS, Cornelius A, Mulligan MJ, et al. Neutralization of viruses with European, South African, and United States SARS-CoV-2 variant spike proteins by convalescent sera and BNT162b2 mRNA vaccine-elicited antibodies. *bioRxiv*. 2021;<https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1>  [Access date: March 4, 2021].
43. Wang P, Liu L, Iketani S, Luo Y, Guo Y, Wang M, et al. Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization. *bioRxiv*. 2021;<https://www.biorxiv.org/content/10.1101/2021.01.25.428137v3>  [Access date: March 4, 2021].
44. Wang P, Wang M, Yu J, et al. Increased Resistance of SARS-CoV-2 Variant P.1 to Antibody Neutralization. *bioRxiv*. 2021;<https://www.biorxiv.org/content/10.1101/2020.12.11.421008v1.full>  [Access date: March 4, 2021].
45. Wang Z, Schmidt F, Weisblum Y, Muecksch F, Barnes CO, Finklin S, et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. *Nature*. 2021.
46. Wu K, Werner AP, Koch M, Choi A, Narayanan E, Stewart-Jones GBE, et al. Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine – Preliminary Report. *N Engl J Med*. 2021.
47. Xie X, Liu Y, Liu J, Zhang X, Zou J, Fontes-Garfias CR, et al. Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. *Nat Med*. 2021.
48. Zhou D, Dejnirattisai W, Supasa P, et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine induced sera. *Cell* 2021;[https://www.cell.com/cell/pdf/S0092-8674\(21\)00226-9.pdf](https://www.cell.com/cell/pdf/S0092-8674(21)00226-9.pdf)   [Access date: March 4, 2021].

49. Chu DK, Akl EA, Duda S, Solo K, Yaacoub S, Schunemann HJ, et al. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. *Lancet*. 2020;395(10242):1973-87.
50. Gallaway MS, Rigler J, Robinson S, Herrick K, Livar E, Komatsu KK, et al. Trends in COVID-19 Incidence After Implementation of Mitigation Measures – Arizona, January 22-August 7, 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69(40):1460-3.
51. Haug N, Geyrhofer L, Londei A, Dervic E, Desvars-Larrive A, Loreto V, et al. Ranking the effectiveness of worldwide COVID-19 government interventions. *Nat Hum Behav*. 2020;4(12):1303-12.
52. Kanu FA, Smith EE, Offutt-Powell T, Hong R, Delaware Case I, Contact Tracing T, et al. Declines in SARS-CoV-2 Transmission, Hospitalizations, and Mortality After Implementation of Mitigation Measures- Delaware, March-June 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69(45):1691-4.
53. Kucharski AJ, Klepac P, Conlan AJK, Kissler SM, Tang ML, Fry H, et al. Effectiveness of isolation, testing, contact tracing, and physical distancing on reducing transmission of SARS-CoV-2 in different settings: a mathematical modelling study. *Lancet Infect Dis*. 2020;20(10):1151-60.
54. Alexander A, Ricco J, Smetters K, et al. Epidemiological and Economic Effects of Lockdown. *Brookings Papers on Economic Activity*. 2020;<https://www.brookings.edu/wp-content/uploads/2020/09/Arnon-et-al-conference-draft.pdf> [Access date: March 4, 2021].
55. Boserup B, McKenney M, Elkbuli A. Alarming trends in US domestic violence during the COVID-19 pandemic. *Am J Emerg Med*. 2020;38(12):2753-5.
56. Brooks SK, Webster RK, Smith LE, Woodland L, Wessely S, Greenberg N, et al. The psychological impact of quarantine and how to reduce it: rapid review of the evidence. *Lancet*. 2020;395(10227):912-20.
57. Czeisler ME, Lane RI, Petrosky E, Wiley JF, Christensen A, Njai R, et al. Mental Health, Substance Use, and Suicidal Ideation During the COVID-19 Pandemic – United States, June 24-30, 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69(32):1049-57.
58. Holland KM, Jones C, Vivolo-Kantor AM, Idaikadar N, Zwald M, Hoots B, et al. Trends in US Emergency Department Visits for Mental Health, Overdose, and Violence Outcomes Before and During the COVID-19 Pandemic. *JAMA Psychiatry*. 2021.
59. McGinty EE, Presskreischer R, Han H, Barry CL. Psychological Distress and Loneliness Reported by US Adults in 2018 and April 2020. *JAMA*. 2020;324(1):93-4.
60. Orben A, Tomova L, Blakemore SJ. The effects of social deprivation on adolescent development and mental health. *Lancet Child Adolesc Health*. 2020;4(8):634-40.
61. UNESCO. Adverse consequences of school closures <https://en.unesco.org/covid19/educationresponse/consequences> [Access date: March 4, 2021] [
62. Galanti M., Pei S., Yamana T.K., et al. The importance of continued non-pharmaceutical interventions during the upcoming SARS-COV-2 vaccination campaign. medRxiv. 2020;<https://www.medrxiv.org/content/10.1101/2020.12.23.20248784v1> [Access date: March 4, 2021].
63. Gozzi N, Bajardi P, Perra N, et al. The importance of non-pharmaceutical interventions during the COVID-19 vaccine rollout. medRxiv. 2021;<https://www.medrxiv.org/content/10.1101/2021.01.09.21249480v1.full.pdf> [March 4, 2021].
64. Gumel A, Iboi E, Ngonghala C, et al. Towards achieving a vaccine-derived herd immunity threshold for COVID-19 in the U.S. medRxiv. 2021;<https://www.medrxiv.org/content/10.1101/2020.12.11.20247916v3> [Access date: March 4, 2020].
65. Iboi EA, Ngonghala CN, Gumel AB. Will an imperfect vaccine curtail the COVID-19 pandemic in the U.S.? *Infect Dis Model*. 2020;5:510-24.
66. Li J, Giabbanelli PJ. Returning to a normal life via COVID-19 vaccines in the USA: a large-scale agent-based simulation study. medRxiv. 2021;<https://www.medrxiv.org/content/10.1101/2021.01.31.21250872v1> [Access date: March 4, 2021].
67. Love J, Keegan L, Angulo F, et al. Continued need for non-pharmaceutical interventions after COVID-19 vaccination in long-term care facilities. medRxiv. 2021;<https://www.medrxiv.org/content/10.1101/2021.01.06.21249339v1.full.pdf> [Access date: March 4, 2021].
68. Tang B, Liu P, Yang J, et al. The challenges of the coming mass vaccination and exit strategy in prevention and control of COVID-19, a modelling study. medRxiv. 2020;<https://www.medrxiv.org/content/10.1101/2020.12.18.20248478v1> [Access date: March 4, 2021].

69. Axios/Ipsos. Poll – Wave 40 <https://www.ipsos.com/sites/default/files/ct/news/documents/2021-03/topline-axios-ipsos-coronavirus-index-w40.pdf>   [Access date: March 4, 2020] [
70. Nguyen KH, Srivastav A, Razzaghi H, Williams W, Lindley MC, Jorgensen C, et al. COVID-19 Vaccination Intent, Perceptions, and Reasons for Not Vaccinating Among Groups Prioritized for Early Vaccination – United States, September and December 2020. *MMWR Morb Mortal Wkly Rep.* 2021;70(6):217-22.
71. Szilagyi P, Thomas K, Shah M, et al. National Trends in the US Public's Likelihood of Getting a COVID-19 Vaccine– April 1 to December 8, 2020. *JAMA.* 2020;325(4):396-8.
72. The Community Guide. Increasing Appropriate Vaccination: Client or Family Incentive Rewards. 2015;<https://www.thecommunityguide.org/sites/default/files/assets/Vaccination-Incentive-Rewards.pdf>   [Access date: March 4, 2021].
73. AP/NORC. Many remain doubtful about getting COVID-19 vaccine <https://apnorc.org/projects/many-remain-doubtful-about-getting-covid-19-vaccine/>  [Access date: March 4, 2021]2020 [
74. Harris Poll. Harris Poll COVID-19 Survey Wave 42. 2020;<https://theharrispoll.com/wp-content/uploads/2020/12/Wave-42-Data-Tabs.pdf>   [Access date: March 4, 2021].
75. Harris Poll. Harris Poll COVID-19 Survey Wave 49. 2021;<https://theharrispoll.com/wp-content/uploads/2021/02/Wave-49-Data-Tabs.pdf>   [Access date: March 4, 2021].

Last Updated Mar. 8, 2021